Elena Lysenko

Elena Lysenko

Auto-generated profile, based on publicly available information

Elena Lysenko

Neurobiological Foundations of Cognitive Development - Neuropsy Lab, HSE University, Moscow, Russian Federation

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2018 in Neurobiology of Disease
Verified
Journal Article
Open access
PDF file
MSMark L. Schultz
Mark L. Schultz
LTLuis Tecedor
Luis Tecedor
ELElena Lysenko
Elena Lysenko
SRShyam Ramachandran
Shyam Ramachandran
CSColleen Stein
Colleen Stein
BDBeverly L. Davidson
Beverly L. Davidson
The neuronal ceroid lipofuscinoses are a class of inherited neurodegenerative diseases characterized by the accumulation of autofluorescent storage material. The most common neuronal ceroid lipofuscinosis has juvenile onset with rapid onset blindness and progressive degeneration of cognitive processes. The juvenile form is caused by mutations in the CLN3 gene, which encodes the protein CLN3. While mouse models of Cln3 deficiency show mild disease phenotypes, it is apparent from patient tissue- and cell-based studies that its loss impacts many cellular processes. Using Cln3 deficient mice, we previously described defects in mouse brain endothelial cells and blood-brain barrier (BBB) permeability. Here we expand on this to other components of the BBB and show that Cln3 deficient mice have increased astrocyte endfeet area. Interestingly, this phenotype is corrected by treatment with a commonly used GAP junction inhibitor, carbenoxolone (CBX). In addition to its action on GAP junctions, CBX has also been proposed to alter lipid microdomains. In this work, we show that CBX modifies lipid microdomains and corrects membrane fluidity alterations in Cln3 deficient endothelial cells, which in turn improves defects in endocytosis, caveolin-1 distribution at the plasma membrane, and Cdc42 activity. In further work using the NIH Library of Integrated Network-based Cellular Signatures (LINCS), we discovered other small molecules whose impact was similar to CBX in that they improved Cln3-deficient cell phenotypes. Moreover, Cln3 deficient mice treated orally with CBX exhibited recovery of impaired BBB responses and reduced autofluorescence. CBX and the compounds identified by LINCS, many of which have been used in humans or approved for other indications, may find therapeutic benefit in children suffering from CLN3 deficiency through mechanisms independent of their original intended use.

1 November 2019 in JCI Insight
Verified
Journal Article
Closed access
PDF file
RARebecca Ahrens-Nicklas
Rebecca Ahrens-Nicklas
LTLuis Tecedor
Luis Tecedor
AHArron F. Hall
Arron F. Hall
ELElena Lysenko
Elena Lysenko
ACAkiva S. Cohen
Akiva S. Cohen
EMEric D. Marsh
Eric D. Marsh
Accumulation of lysosomal storage material and late-stage neurodegeneration are hallmarks of lysosomal storage disorders (LSDs) affecting the brain. Yet, for most LSDs, including CLN3 disease, the most common form of childhood dementia, it is unclear what mechanisms drive neurologic symptoms. Do deficits arise from loss of function of the mutated protein or toxicity from storage accumulation? Here, using in vitro voltage-sensitive dye imaging and in vivo electrophysiology, we find progressive hippocampal dysfunction occurs before notable lysosomal storage and neuronal loss in 2 CLN3 disease mouse models. Pharmacologic reversal of lysosomal storage deposition in young mice does not rescue this circuit dysfunction. Additionally, we find that CLN3 disease mice lose an electrophysiologic marker of new memory encoding — hippocampal sharp-wave ripples. This discovery, which is also seen in Alzheimer’s disease, suggests the possibility of a shared electrophysiologic signature of dementia. Overall, our data describe new insights into previously unknown network-level changes occurring in LSDs affecting the central nervous system and highlight the need for new therapeutic interventions targeting early circuit defects.

8 July 2022 in Neuropsychology Review
Verified
Journal Article
Closed access
PDF file
ELElena S. Lysenko
Elena S. Lysenko
MBMariia D. Bogdanova
Mariia D. Bogdanova
MAMarie Arsalidou
Marie Arsalidou